Pfizer Inc (NYSE:PFE) has reportedly secured a major contract with the U.K. to supply millions of doses of its Abrysvo respiratory syncytial virus (RSV) vaccine, edging out local pharmaceutical giant GSK Plc (NYSE:GSK). This agreement includes over 3.5 million doses for older adults and more than 1.4 million doses for pregnant mothers in England and Northern Ireland over the next two years. Related: GSK’s Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales. The decision revealed through a redacted contract, represents a significant blow to GSK, which is in fierce competition with Pfizer to dominate the emerging ...